US Patent Issued to Genzyme on Nov. 18 for "scFv-Fc dimers that bind transforming growth factor-Beta1 with high affinity, avidity and specificity" (New Jersey, Massachusetts Inventors)

ALEXANDRIA, Va., Nov. 18 -- United States Patent no. 12,473,356, issued on Nov. 18, was assigned to Genzyme Corp. (Cambridge, Mass.).

"scFv-Fc dimers that bind transforming growth factor-Beta1 with high affinity, avidity and specificity" was invented by Huawei Qiu (Bridgewater, N.J.), Clark Pan (Sudbury, Mass.) and Julie Bird (Bridgewater, N.J.).

According to the abstract* released by the U.S. Patent & Trademark Office: "An scFv-Fc dimer binds and neutralizes TGFBeta1 selectively and with high affinity and avidity. The scFv region may comprise the same VH and VL domains or CDR regions as metelimumab. The unique combination of their smaller size, high selectivity, potency against TGFBeta1, and long in vivo half-life makes the scFv-Fc dimer...